Prothena Corp Public (PRTA) Non-Current Deffered Revenue (2012 - 2025)
Prothena Corp Public (PRTA) posted quarterly Non-Current Deffered Revenue of $1.6 million for Q1 2025, down 97.59% year-over-year from $67.4 million in Q1 2024, and down 52.96% quarter-over-quarter from $3.4 million in Q4 2024.
Prothena Corp Public (PRTA) Non-Current Deffered Revenue (2012 - 2025) Analysis & Trends
Prothena Corp Public's Non-Current Deffered Revenue history runs 14 years deep, the most recent figure standing at $1.6 million for Q1 2025.
- In Q1 2025, Non-Current Deffered Revenue fell 97.59% year-over-year to $1.6 million; the TTM figure through Mar 2025 stood at $1.6 million (down 97.59% YoY), while the FY2024 annual figure was $3.4 million, down 94.88% from the prior year.
- Non-Current Deffered Revenue for Q1 2025 stood at $1.6 million, down from $3.4 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $110.2 million in Q1 2021, with the low at $1.6 million in Q1 2025.
- The 5-year median for Non-Current Deffered Revenue is $85.3 million (2021), against an average of $68.1 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue gained 15.31% in 2022, then tumbled 97.59% in 2025.
- Prothena Corp Public's Non-Current Deffered Revenue stood at $102.9 million in 2021, then decreased by 17.14% to $85.3 million in 2022, then fell by 20.97% to $67.4 million in 2023, then tumbled by 94.88% to $3.4 million in 2024, then tumbled by 52.96% to $1.6 million in 2025.
- Business Quant data shows PRTA's Non-Current Deffered Revenue at $1.6 million in Q1 2025, $3.4 million in Q4 2024, and $5.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 5.60 Mn |
| Jun 30, 2024 | 7.37 Mn |
| Mar 31, 2024 | 67.41 Mn |
| Dec 31, 2023 | 67.41 Mn |
| Sep 30, 2023 | 67.41 Mn |
| Jun 30, 2023 | 67.41 Mn |
| Mar 31, 2023 | 85.29 Mn |
| Dec 31, 2022 | 85.29 Mn |
| Sep 30, 2022 | 96.99 Mn |
| Jun 30, 2022 | 98.35 Mn |
| Mar 31, 2022 | 100.64 Mn |
| Dec 31, 2021 | 102.93 Mn |
| Sep 30, 2021 | 104.56 Mn |
| Jun 30, 2021 | 85.29 Mn |
| Mar 31, 2021 | 110.24 Mn |
| Dec 31, 2020 | 110.24 Mn |
| Sep 30, 2020 | 110.24 Mn |
| Jun 30, 2020 | 110.24 Mn |